CoChat

Benzodiazepine Abuse and Addiction

Umbricht, Annie, Velez, Martha L. · 2015 · Textbook of Addiction Treatment: International Perspectives

The DOI matches its Crossref record; 62 of the 63 references it cites were found in a registry or an index.

Abstract

Chlordiazepoxide’s sedative activity was serendipitously discovered by Sternbach in 1955 in Basel, Switzerland, and this first benzodiazepine (BZD) was introduced in 1960 for the treatment of anxiety and insomnia, followed shortly by diazepam in 1963. Given their lower toxicity, BZDs soon replaced barbiturates and other hypnotic drugs, and they became widely prescribed. Although generally considered effective and safe for short-term use for a wide range of conditions, the long-term use of BZDs is much more controversial as they lose efficacy and have been associated with adverse reactions. Problems associated with long-term use include rebound of the symptoms for which they were prescribed, alteration of sleep architecture with loss of sleep efficiency, nightmares, agitation, anterograde amnesia leading to cognitive impairment, confusion, depression, psychomotor compromise with increased risk of falls and motor vehicle accidents, withdrawal symptoms upon discontinuation, and risk of dependence and abuse in special populations. In the late 1980s and early 1990s, a new group of GABAA receptor agonists at the benzodiazepine receptor site, the Z-drugs, was introduced for the treatment of insomnia, the most common being zaleplon, zolpidem, zopiclone, and its s-enantiomer eszopiclone. Chemically distinct from the benzodiazepine group, they have been promoted to be safer than traditional BZDs and gained wide acceptance with the public and practitioners. However, given their site of action at the benzodiazepine site of the GABAAR, complications are expected to be similar. In fact, the FDA, on May 14, 2013, released a safety announcement recommending a dose reduction for zolpidem extended release as well as a warning not to operate a vehicle or machinery requiring complete mental alertness on the day following the use of zolpidem due to residual psychomotor impairment. Next day sedation, physical dependence and withdrawal, cognitive and psychomotor problems are found in patients receiving Z-drugs. Abuse of the Z-drugs is on the increase and studies suggest that Z-drugs may also increase the risk of depression. Clinicians prescribing sedatives should ensure short-term use to maximize benefit while minimizing misuse and diversion. They can play a critical role in identifying patients at risk to misuse or divert prescription drugs. Several studies demonstrate that BZD discontinuation in patients with long-term use and dependence is associated with improved quality of life. The management of the patients with BDZ abuse and/or dependence and interventions for BZD detoxification will be described. © Springer-Verlag Italia 2015

Overview

Integrity signals

Registry

Crossref · 10.1007/978-88-470-5322-9_102

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 62 references

Cited by

See all 3

Metadata

Authors
Umbricht, A., & Velez, M. L.
Affiliations
Johns Hopkins University (US)
Corresponding author
Umbricht, Annie
Venue
Textbook of Addiction Treatment: International Perspectives
Published
2014-11-30
Pages
343-365
OpenAlex
W1951689711
Cited by
3
References
63
Citations by year
2025: 1 · 2017: 2
FWCI
2.05
Type
book chapter
Language
en
Open access
closed
Licence
Locations
Springer eBooks (publishedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
Keywords
benzodiazepine misuse, benzodiazepine dependence, Z-drugs, zolpidem, zaleplon, zopiclone, eszopiclone, GABA-A receptor agonists, drug addiction, withdrawal symptoms, psychomotor impairment, insomnia treatment, prescription drug misuse, drug diversion, cognitive impairment, depression risk

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Benzodiazepine Abuse and Addiction. https://app.cochat.ai/papers/10.1007/978-88-470-5322-9_102
The paper
Umbricht, A., & Velez, M. L. (2015). Benzodiazepine Abuse and Addiction. Textbook of Addiction Treatment: International Perspectives. https://doi.org/10.1007/978-88-470-5322-9_102

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.